The deal is expected to be closed by the end of December 2026 and will be funded by an optimal mix of debt and equity.

Gujarat Themis Biosyn To Acquire Sanofi Portfolio For Rs 1,700 Crore

Gujarat Themis Biosyn Ltd. will acquire a portfolio of anti-tuberculosis (TB) and anti-infective brands from Sanofi, the French-holding company of the Sanofi group. The company has entered into an Asset Purchase Agreement for acquisition of 13 established branded generic products with a strong presence across more than 55 countries in Europe, the Middle East and Africa for Euro 158 million or Rs 1,740 crore payable in cash at closing, according to a stock exchange filing late Thursday.

Notably, the value of the deal is nearly half the current market capitalisation of Gujarat Themis Biosyn of Rs 3,520 crore.

The deal is expected to be closed by the end of December 2026 and will be funded by an optimal mix of debt and equity. The transaction is expected to be earnings (EPS) accretive, supported by profitable branded generics sales, vertical integration and improved operating leverage, GTBL said.

"The acquisition would include marketing authorizations, brands, regulatory dossiers, and inventory and associated commercial rights. The transaction does not involve the transfer of manufacturing facilities or employees, making it a capital-efficient and assetlight expansion for the company," a statement said.

The concerned portfolio reported net sales of approximately Euro 62 million for the year ended 2025. GTBL said the acquisition will strengthen its global pharmaceuticals platform and expand its presence in the anti-infective segment.

"The deal would provide immediate access to regulated and semi-regulated markets, enabling GTBL to enhance its international footprint. It would also create a strong opportunity for forward integration, allowing the company to leverage its existing capabilities in fermentation-based intermediates and APIs to support the acquired finished dosage formulations portfolio and drive improved realisations across the value chain," the company said.

ALSO READ: Chronic Burden: Hypertension, Diabetes, Cholesterol Drugs Dominate 40% Of Indian Pharma Landscape